Patents by Inventor Feng-Shiun Shie

Feng-Shiun Shie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combined therapy for treating Alzheimer's disease
    Patent number: 11793775
    Abstract: The disclosure provides a therapeutic method for preventing, ameliorating and/or treating Alzheimer's disease in a subject in need of such treatment. The therapeutic method comprises administrating to said subject a pharmaceutical combination comprising an effective amount of curcumin analog, TML-6 and an effective amount of an anti-A beta (A?) antibody.
    Type: Grant
    Filed: April 20, 2022
    Date of Patent: October 24, 2023
    Assignees: MERRY LIFE BIOMEDICAL COMPANY, LTD., NATIONAL HEALTH RESEARCH INSTITUTES
    Inventors: Ih-Jen Su, Feng-Shiun Shie
  • COMBINED THERAPY FOR TREATING ALZHEIMER'S DISEASE
    Publication number: 20220362180
    Abstract: The disclosure provides a therapeutic method for preventing, ameliorating and/or treating Alzheimer's disease in a subject in need of such treatment. The therapeutic method comprises administrating to said subject a pharmaceutical combination comprising an effective amount of curcumin analog, TML-6 and an effective amount of an anti-A beta (A?) antibody.
    Type: Application
    Filed: April 20, 2022
    Publication date: November 17, 2022
    Inventors: Ih-Jen SU, Feng-Shiun SHIE
  • Anti-Abeta antibodies and uses thereof
    Patent number: 11084873
    Abstract: An isolated antibody, comprising a light-chain CDR1 (L-CDR1) having the sequence of SEQ ID NO: 1, SEQ ID NO: 7, or SEQ ID NO: 14; a light-chain CDR2 (L-CDR2) having the sequence of SEQ ID NO: 2 or SEQ ID NO: 15; a light-chain CDR3 (L-CDR3) having the sequence of SEQ ID NO: 3, SEQ ID NO: 8, SEQ ID NO: 21, or SEQ ID NO: 24; a heavy-chain CDR1 (H-CDR1) having the sequence of SEQ ID NO: 4, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 16, or SEQ ID NO: 25; a heavy-chain CDR2 (H-CDR2) having the sequence of SEQ ID NO: 5, SEQ ID NO: 12, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 22, or SEQ ID NO: 26; and a heavy-chain CDR3 (H-CDR3) having the sequence of SEQ ID NO: 6, SEQ ID NO: 10, SEQ ID NO: 13, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 23, or SEQ ID NO: 27, wherein the antibody specifically binds to A?1-42 or an N-terminal modified form thereof.
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: August 10, 2021
    Assignee: National Health Research Institutes
    Inventors: Feng-Shiun Shie, Tsu-An Hsu, Chuan Shih, Santai Shen
  • ANTI-Abeta ANTIBODIES AND USES THEREOF
    Publication number: 20190367593
    Abstract: An isolated antibody, comprising a light-chain CDR1 (L-CDR1) having the sequence of SEQ ID NO: 1, SEQ ID NO: 7, or SEQ ID NO: 14; a light-chain CDR2 (L-CDR2) having the sequence of SEQ ID NO: 2 or SEQ ID NO: 15; a light-chain CDR3 (L-CDR3) having the sequence of SEQ ID NO: 3, SEQ ID NO: 8, SEQ ID NO: 21, or SEQ ID NO: 24; a heavy-chain CDR1 (H-CDR1) having the sequence of SEQ ID NO: 4, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 16, or SEQ ID NO: 25; a heavy-chain CDR2 (H-CDR2) having the sequence of SEQ ID NO: 5, SEQ ID NO: 12, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 22, or SEQ ID NO: 26; and a heavy-chain CDR3 (H-CDR3) having the sequence of SEQ ID NO: 6, SEQ ID NO: 10, SEQ ID NO: 13, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 23, or SEQ ID NO: 27, wherein the antibody specifically binds to A?1-42 or an N-terminal modified form thereof.
    Type: Application
    Filed: May 30, 2019
    Publication date: December 5, 2019
    Inventors: Feng-Shiun Shie, Tsu-An Hsu, Chuan Shih, Santai Shen
  • Treatment of neurodegenerative disorders with thiourea compounds
    Patent number: 8198284
    Abstract: A method for treating a neurodegenerative disorder. The method includes administering to a subject in need thereof an effective amount of one or more thiourea compounds of formula (I) or (II): Each variable in formula (I) or (II) is defined herein. Also disclosed is use of these thiourea compounds to reduce microglia-mediated neuro-inflammation or enhancing microglial phagocytosis of A?.
    Type: Grant
    Filed: March 24, 2009
    Date of Patent: June 12, 2012
    Assignee: National Health Research Institutes
    Inventors: Feng-Shiun Shie, Jyh-Haur Chern, Yu-Sheng Chao
  • Treatment of Neurodegenerative Disorders with Thiourea Compounds
    Publication number: 20090275596
    Abstract: A method for treating a neurodegenerative disorder. The method includes administering to a subject in need thereof an effective amount of one or more thiourea compounds of formula (I) or (II): Each variable in formula (I) or (II) is defined herein. Also disclosed is use of these thiourea compounds to reduce microglia-mediated neuro-inflammation or enhancing microglial phagocytosis of A?.
    Type: Application
    Filed: March 24, 2009
    Publication date: November 5, 2009
    Applicant: National Health Research Institutes
    Inventors: Feng-Shiun Shie, Jyh-Haur Chern, Yu-Sheng Chao
  • Methods and compositions for the treatment of neurological diseases and disorders
    Publication number: 20070232556
    Abstract: Methods and compositions are provided for preventing or treating neurodegenerative disease and other related diseases and disorders in a mammalian subject. The method provides administering to the mammalian subject a compound capable of inhibiting a PGE2 receptor, e.g., subtype EP2, wherein the compound is administered in an amount effective to treat the neurodegenerative disease or to prevent its occurrence or recurrence. A method for identifying compounds capable of inhibiting neurodegenerative disease is also provided.
    Type: Application
    Filed: March 31, 2006
    Publication date: October 4, 2007
    Inventors: Thomas Montine, Feng-Shiun Shie